Since its U.S. approval last fall, Relyvrio, the amyotrophic lateral sclerosis drug made by Amylyx Pharmaceuticals Inc., has turned its maker into a profitable company — and kept that streak going for six months straight.
Since its U.S. approval last fall, Relyvrio, the amyotrophic lateral sclerosis drug made by Amylyx Pharmaceuticals Inc., has turned its maker into a profitable company — and kept that streak going for six months straight.
